* Preclinical data demonstrate that ipi-549 targets immune
cells, alters immune-suppressive microenvironment
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
The post BRIEF-Infinity Pharma announces new preclinical data for IPI-549 appeared first on NASDAQ.